Feasibility, Safety, and Preliminary Efficacy of Intermittent Theta Burst Stimulation Targeting the Left Dorsolateral Prefrontal Cortex in Older Adults with Chronic Low Back Pain with or without Comorbid Chronic Knee Pain: A Pilot Randomized Sham- Controlled Trial
This pilot randomized sham-controlled trial demonstrates that intermittent theta burst stimulation targeting the left dorsolateral prefrontal cortex is feasible, safe, and well-tolerated in older adults with chronic low back pain, successfully modulating frontoparietal brain activity during cognitive tasks despite both active and sham groups reporting reduced pain intensity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For many older adults, the daily reality of chronic pain is more than just a physical ache; it is a heavy weight that can cloud the mind. When the body is in constant discomfort, the brain's ability to focus, switch tasks, and make decisions often suffers, creating a difficult cycle where pain and cognitive decline feed into one another. Scientists have long suspected that these two problems share a common root in the brain's wiring, specifically in a region known as the left dorsolateral prefrontal cortex. This area acts as a command center, helping to manage both the emotional weight of pain and the complex mental work required for daily life. Because older adults are often at risk of side effects from pain medications, researchers are eager to find non-drug ways to reset this system. One promising approach involves a technique called intermittent theta burst stimulation, which uses magnetic pulses to gently nudge the brain's activity, much like a tuning fork might bring a musical instrument back into pitch. The goal is to see if targeting this specific brain region can simultaneously ease the burden of chronic pain and sharpen the mind.
A team of researchers recently put this idea to the test in a carefully controlled experiment involving thirty older adults, aged sixty to eighty-five, who lived with chronic lower back pain, with some also suffering from chronic knee pain. The study was designed as a pilot trial, a smaller-scale investigation meant to determine if a larger, definitive study could be successfully conducted. The participants were divided into two groups: one received the actual magnetic stimulation over the left side of the forehead, while the other received a fake version that felt and sounded exactly the same but did not deliver the magnetic pulse to the brain. Over the course of two weeks, everyone attended twelve sessions, with two treatments per day. The researchers were not just looking to see if the treatment worked; they were primarily checking if the protocol was safe, if the older adults could tolerate the schedule, and if the study design was practical enough to move forward.
The results of this initial test were overwhelmingly positive regarding the feasibility of the approach. The study ran smoothly, with nearly all participants completing the full two-week course, and no one experienced any serious side effects. The few minor issues reported, such as temporary headaches or mild discomfort at the stimulation site, were common and manageable. The participants found the experience acceptable, and the researchers successfully kept the participants unaware of whether they were receiving the real treatment or the fake one, which is crucial for a fair comparison. This high level of success in recruitment, retention, and safety confirmed that the "green light" was on to proceed with a much larger study in the future.
When it came to the actual effects on pain and thinking, the findings were more nuanced and revealed some unexpected twists. Both groups, whether they received the real stimulation or the fake one, reported a significant reduction in their lower back pain intensity over time. However, this improvement was similar in both groups, meaning the real magnetic stimulation did not outperform the placebo in reducing pain during this short trial. Interestingly, the pain in the knees did not change for either group. In a surprising turn regarding mental performance, the group that received the fake treatment actually showed a slight improvement in a specific type of mental task involving stopping and starting actions, while the group receiving the real treatment did not show this same immediate boost. The researchers suggest that the real treatment might have triggered a period of brain reorganization that takes time to settle, whereas the improvement in the fake group was likely due to simple practice with the tasks.
Despite the lack of immediate superiority in pain relief or cognitive scores, the study uncovered a unique biological signal. Using brain imaging, the researchers observed that the group receiving the real stimulation changed how their brains activated during complex thinking tasks. Specifically, the real treatment seemed to stabilize the activity in the networks responsible for switching between different mental tasks, preventing the brain from becoming less active as the participants got used to the tests. This suggests that the treatment is indeed influencing the brain's neural pathways, even if those changes had not yet translated into a clear, measurable advantage in pain or thinking speed during the short study period. The researchers also noted a small, temporary dip in sleep quality for the group receiving the real treatment, a side effect that warrants attention in future studies.
Ultimately, this pilot study serves as a vital proof of concept. It demonstrates that targeting the left side of the prefrontal cortex with magnetic pulses is safe and well-tolerated by older adults with chronic pain. While the treatment did not immediately cure pain or boost thinking skills better than a placebo in this small group, it successfully altered brain activity in a way that aligns with the goal of improving executive function. The findings provide a solid foundation for a larger, more comprehensive trial that will use these insights to refine the treatment, potentially adjusting the dosage or duration to unlock the full therapeutic potential for those living with the dual burden of chronic pain and cognitive decline.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.